Stoke and Biogen Release Zorevunersen Study Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy BIIB?
Source: NASDAQ.COM
- Study Results Released: Stoke Therapeutics and Biogen announced the publication of data on the investigational drug Zorevunersen, indicating its potential for disease modification in patients with Dravet syndrome, marking a significant advancement in treatment options.
- Clinical Trial Data: Results from two completed Phase 1/2a trials and ongoing open-label extension studies demonstrated substantial and durable reductions in seizures, along with improvements across multiple cognitive and behavioral measures, indicating long-term efficacy.
- Future Research Outlook: Barry Ticho, Chief Medical Officer of Stoke, stated that Zorevunersen could become the first disease-modifying medicine for Dravet syndrome, with anticipation for the Phase 3 EMPEROR study results expected in mid-2027 to further validate its efficacy.
- Market Reaction: Stoke shares closed at $34.42 on Nasdaq, up 1.89%, reflecting positive market expectations regarding the drug's potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 187.570
Low
143.00
Averages
204.45
High
246.00
Current: 187.570
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA GREENLIGHTS NEW HIGH-DOSE TREATMENT PLAN FOR SPINRAZA® (NUSINERSEN) IN SPINAL MUSCULAR ATROPHY
FDA Approval: The FDA has approved a new high-dose regimen of Spinraza® (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Treatment Impact: This approval is expected to enhance treatment options for patients suffering from SMA, a genetic disorder affecting muscle strength and movement.
See More
Biogen Reports Positive Results for Litifilimab in Lupus Study
- Clinical Trial Success: Biogen's AMETHYST Phase 2/3 study of litifilimab demonstrated a statistically significant 11.8% reduction in skin disease activity compared to placebo at Week 16, indicating the potential for the drug to become the first innovative therapy for cutaneous lupus erythematosus in 70 years.
- Efficacy Assessment: The study revealed rapid and sustained improvements in skin disease activity over 24 weeks, with separation from placebo observed as early as Week 4, and a higher proportion of participants achieving CLASI-50 and CLASI-70 responses, underscoring the drug's effectiveness.
- Safety Profile: Over 24 weeks, adverse events occurred in 74.6% of litifilimab participants compared to 64.7% in the placebo group, with most events being mild to moderate; however, serious adverse events were reported in 6.8% of the litifilimab group, higher than the 2.9% in the placebo group.
- Market Reaction: Although Biogen's stock fell by 3.78% to $183.84 on March 27, it rebounded to $185.01 in after-hours trading, reflecting optimistic market sentiment regarding the drug's prospects.
See More
Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Announcement: Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, resulting in a 140% surge in Apellis' shares during Tuesday's pre-market trading, indicating strong market enthusiasm and a significant boost to Biogen's position in the rare disease treatment sector.
- Retail Sentiment: Following the acquisition news, retail sentiment around Apellis on Stocktwits trended bullish with high message volumes, reflecting investor optimism about the company's future prospects, which could further drive up its stock price.
- Business Expansion: This acquisition will enhance Biogen's rare disease treatment portfolio and accelerate its expansion into nephrology, signaling a strategic shift towards high-growth areas to capture increasing market demand.
- Investor Attention: As the acquisition progresses, market focus on Apellis has intensified, with investors likely to closely monitor the integration process and its impact on Biogen's overall performance, suggesting potential future stock price volatility.
See More
Biogen to Acquire Apellis for $5.6 Billion
- Acquisition Agreement: Biogen has entered into a definitive agreement to acquire all outstanding shares of Apellis Pharmaceuticals for $41.00 per share in cash, totaling approximately $5.6 billion, reflecting Biogen's strong confidence in Apellis's future growth potential.
- Additional Payment Structure: Apellis shareholders will receive a nontransferable CVR entitling them to two payments of $2 per share, contingent on meeting specific global net sales thresholds, which not only enhances shareholder potential returns but also incentivizes Apellis's performance.
- Earnings Outlook Improvement: The acquisition is expected to significantly boost Biogen's non-GAAP EPS starting in 2027, with a compounded annual growth rate enhancing the company's profitability through the end of the decade, indicating a positive outlook for Biogen's future financial performance.
- Positive Market Reaction: In pre-market trading on Nasdaq, Apellis shares surged 140.5% to $41.10, indicating a favorable market response to the acquisition, which may further strengthen Biogen's market position.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
FDA GREENLIGHTS NEW HIGH-DOSE TREATMENT PLAN FOR SPINRAZA® (NUSINERSEN) IN SPINAL MUSCULAR ATROPHY
FDA Approval: The FDA has approved a new high-dose regimen of Spinraza® (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Treatment Impact: This approval is expected to enhance treatment options for patients suffering from SMA, a genetic disorder affecting muscle strength and movement.
See More
Biogen Reports Positive Results for Litifilimab in Lupus Study
- Clinical Trial Success: Biogen's AMETHYST Phase 2/3 study of litifilimab demonstrated a statistically significant 11.8% reduction in skin disease activity compared to placebo at Week 16, indicating the potential for the drug to become the first innovative therapy for cutaneous lupus erythematosus in 70 years.
- Efficacy Assessment: The study revealed rapid and sustained improvements in skin disease activity over 24 weeks, with separation from placebo observed as early as Week 4, and a higher proportion of participants achieving CLASI-50 and CLASI-70 responses, underscoring the drug's effectiveness.
- Safety Profile: Over 24 weeks, adverse events occurred in 74.6% of litifilimab participants compared to 64.7% in the placebo group, with most events being mild to moderate; however, serious adverse events were reported in 6.8% of the litifilimab group, higher than the 2.9% in the placebo group.
- Market Reaction: Although Biogen's stock fell by 3.78% to $183.84 on March 27, it rebounded to $185.01 in after-hours trading, reflecting optimistic market sentiment regarding the drug's prospects.
See More
Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Announcement: Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, resulting in a 140% surge in Apellis' shares during Tuesday's pre-market trading, indicating strong market enthusiasm and a significant boost to Biogen's position in the rare disease treatment sector.
- Retail Sentiment: Following the acquisition news, retail sentiment around Apellis on Stocktwits trended bullish with high message volumes, reflecting investor optimism about the company's future prospects, which could further drive up its stock price.
- Business Expansion: This acquisition will enhance Biogen's rare disease treatment portfolio and accelerate its expansion into nephrology, signaling a strategic shift towards high-growth areas to capture increasing market demand.
- Investor Attention: As the acquisition progresses, market focus on Apellis has intensified, with investors likely to closely monitor the integration process and its impact on Biogen's overall performance, suggesting potential future stock price volatility.
See More
Biogen to Acquire Apellis for $5.6 Billion
- Acquisition Agreement: Biogen has entered into a definitive agreement to acquire all outstanding shares of Apellis Pharmaceuticals for $41.00 per share in cash, totaling approximately $5.6 billion, reflecting Biogen's strong confidence in Apellis's future growth potential.
- Additional Payment Structure: Apellis shareholders will receive a nontransferable CVR entitling them to two payments of $2 per share, contingent on meeting specific global net sales thresholds, which not only enhances shareholder potential returns but also incentivizes Apellis's performance.
- Earnings Outlook Improvement: The acquisition is expected to significantly boost Biogen's non-GAAP EPS starting in 2027, with a compounded annual growth rate enhancing the company's profitability through the end of the decade, indicating a positive outlook for Biogen's future financial performance.
- Positive Market Reaction: In pre-market trading on Nasdaq, Apellis shares surged 140.5% to $41.10, indicating a favorable market response to the acquisition, which may further strengthen Biogen's market position.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
